Abstract
Choline Kinase (ChoK) comprises a family of cytosolic enzymes involved in the synthesis of phosphatidylcholine (PC), the most abundant phospholipid in eukaryotic cell membranes. One of the ChoK isoforms, Choline Kinase α (ChoKα), is found over expressed in human tumours. Chemical inhibitors able to interfere with ChoK activity have proven to be effective antitumoral drugs in vitro and in vivo. To validate the use of selective ChoKα inhibitors in cancer therapy, we have developed a genetic strategy to interfere specifically with ChoKα activity based on the generation of a shRNA against the alpha isoform of ChoK. Here we demonstrate that specific inhibition of ChoKα by shRNA has antitumor activity. The specific depletion of ChoKα induces apoptosis in several tumor-derived cell lines from breast, bladder, lung and cervix carcinoma tumors, while the viability of normal primary cells is not affected. Furthermore, this selective antiproliferative effect is achieved both under in vitro and in vivo conditions, as demonstrated by an inducible ChoKα suppression system in human tumour xenografts. These results demonstrate that ChoKα inhibition is a useful antitumoral strategy per se, and provides definitive and non-ambiguous evidence that ChoKα can be used as an efficient and selective drug target for cancer therapy.
Keywords: Choline Kinase, anticancer drugs, target validation, apoptosis, ChoK Inhibitors, shRNA
Current Cancer Drug Targets
Title: Choline Kinase Alpha Depletion Selectively Kills Tumoral Cells
Volume: 8 Issue: 8
Author(s): Monica Banez-Coronel, Ana Ramirez de Molina, Agustin Rodriguez-Gonzalez, Jacinto Sarmentero, Mª Angeles Ramos, Miguel Angel Garcia-Cabezas, Lourdes Garcia-Oroz and Juan Carlos Lacal
Affiliation:
Keywords: Choline Kinase, anticancer drugs, target validation, apoptosis, ChoK Inhibitors, shRNA
Abstract: Choline Kinase (ChoK) comprises a family of cytosolic enzymes involved in the synthesis of phosphatidylcholine (PC), the most abundant phospholipid in eukaryotic cell membranes. One of the ChoK isoforms, Choline Kinase α (ChoKα), is found over expressed in human tumours. Chemical inhibitors able to interfere with ChoK activity have proven to be effective antitumoral drugs in vitro and in vivo. To validate the use of selective ChoKα inhibitors in cancer therapy, we have developed a genetic strategy to interfere specifically with ChoKα activity based on the generation of a shRNA against the alpha isoform of ChoK. Here we demonstrate that specific inhibition of ChoKα by shRNA has antitumor activity. The specific depletion of ChoKα induces apoptosis in several tumor-derived cell lines from breast, bladder, lung and cervix carcinoma tumors, while the viability of normal primary cells is not affected. Furthermore, this selective antiproliferative effect is achieved both under in vitro and in vivo conditions, as demonstrated by an inducible ChoKα suppression system in human tumour xenografts. These results demonstrate that ChoKα inhibition is a useful antitumoral strategy per se, and provides definitive and non-ambiguous evidence that ChoKα can be used as an efficient and selective drug target for cancer therapy.
Export Options
About this article
Cite this article as:
Banez-Coronel Monica, de Molina Ramirez Ana, Rodriguez-Gonzalez Agustin, Sarmentero Jacinto, Ramos Angeles Mª, Garcia-Cabezas Angel Miguel, Garcia-Oroz Lourdes and Lacal Carlos Juan, Choline Kinase Alpha Depletion Selectively Kills Tumoral Cells, Current Cancer Drug Targets 2008; 8 (8) . https://dx.doi.org/10.2174/156800908786733432
DOI https://dx.doi.org/10.2174/156800908786733432 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Curcumin Targets Circulating Cancer Stem Cells by Inhibiting Self-Renewal Efficacy in Non-Small Cell Lung Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Roles of miRNA in the Initiation and Development of Colorectal Carcinoma
Current Pharmaceutical Design Current and Potential Treatments for Cervical Cancer
Current Cancer Drug Targets Chemokines as Pharmacological Targets
Mini-Reviews in Medicinal Chemistry Treatment of Lung Cancer Using Nanoparticle Drug Delivery Systems
Current Drug Discovery Technologies Is Fibroblast Growth Factor Receptor 4 a Suitable Target of Cancer Therapy?
Current Pharmaceutical Design Best Practices and Emerging Trends for Market Access to Personalised Medicine in the US and EU: Learnings for Global Developed and Emerging Markets
Current Pharmacogenomics and Personalized Medicine Proteolytic Cleavage of Notch: “HIT and RUN”
Current Molecular Medicine Two Novel Tri-Aryl Derivatives Attenuate the Invasion-Promoting Effects of Stromal Mesenchymal Stem Cells on Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Discovery and Development of Endocannabinoid-Hydrolyzing Enzyme Inhibitors
Current Topics in Medicinal Chemistry Subject Index to Volume 10
Current Medicinal Chemistry Progesterone Receptor Agonists and Antagonists as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Role of the Akt Pathway in Prostate Cancer
Current Cancer Drug Targets A Review on Exploring Better Safety Prospects in Managing Cancer using Liposomal Combinations of Food Bioactive Compounds and Anticancer Drugs: Combisomes
Current Drug Delivery Bioactive Constituents from an Endophytic Fungus, Penicillium polonicum NFW9, Associated with Taxus fauna
Medicinal Chemistry Vitamin D and Cardiovascular Disease
Current Vascular Pharmacology Cachexia and Herbal Medicine: Perspective
Current Pharmaceutical Design Differential Regulation of microRNAs in Patients with Ischemic Stroke
Current Neurovascular Research Clinical Experiment of Mutant Herpes Simplex Virus HF10 Therapy for Cancer
Current Cancer Drug Targets Effects of Radiation on Drug Metabolism: A Review
Current Drug Metabolism